ClinicalTrials.gg
Active, not recruitingNCT05453058TALISMANUpdated Dec 8, 2025

Observational Study in Multiple System Atrophy

An observational study in Multiple System Atrophy, sponsored by H. Lundbeck A/S. Active, not recruiting at 8 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by H. Lundbeck A/S · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Multiple System Atrophy with a site in China — 18 open to participants now, 19 under way, 1 of them phase 3. Multiple System Atrophy · China.

Planned enrollment
7th of 13
90 · median 90
Started
2022
with 1 other
Observational
13 of 26
8 open now
Primary completion
2024-03
later than 0 of 18 live
Registered
5th of 26
by date
Lead sponsor
1 of 26
H. Lundbeck A/S

Among the 26 studies in Multiple System Atrophy with a site in China, this one is the 7th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2022, is one of 13 observational ones, reaches primary completion later than 0 of the 18 other live ones, and was the 5th registered.

Multiple System Atrophy

207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.

Browse Multiple System Atrophy studies →

Open to participants now

18 of the 26 studies in Multiple System Atrophy with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Multiple System Atrophy with a site in China, or all of them as a file.
02

Study summary

Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union [EU]). There will be common study objectives between China and EU regions (including prospective assessments for MSA disease progression during routine clinical visits for MSA), and this will allow for data (on common objectives) to be presented overall and stratified by region. There will also be study objectives specific to each region: 1) the clinical assessment for MSA (Unified MSA Rating Scale [UMSARS]) has not been validated using standardised methods in China, and so the psychometric properties of the Chinese version of the UMSARS will be examined in Chinese patients in this study; 2) there will be retrospective assessments and prospective protocol-mandated assessments (of Magnetic Resonance Imaging [MRI] and bloods biomarkers) and study visits for EU patients.

Because some study objectives are the same for China and the EU (i.e., prospective assessments during routine clinical visits for MSA), and other objectives are specific to each region, there will be one regional protocol for China and one regional protocol for the EU; each describing the study assessments relevant to each region.

Read the detailed description

Multiple system atrophy (MSA) is a sporadic, rapidly progressing neurodegenerative disorder. Most MSA patients are diagnosed between 50 to 60 years of age and the mean survival time is 6 to 10 years from symptom onset, with few surviving more than 15 years from symptom onset. The rapid progression and complexity of the disease, as well as its unresponsiveness to drugs, such as Levodopa for parkinsonian symptoms, makes MSA a challenging disease to treat. Based on the predominant motor features at the time of clinical evaluation, MSA is classified as either MSA with predominant parkinsonism (MSA-P) or MSA with predominant cerebellar ataxia (MSA-C).

MSA is an orphan and rare disease. The prevalence estimate of MSA is 3 to 5 per 100,000 in the general population. The prevalence estimate ranges from 2 to 5 per 100,000 in the United States and European Union (EU) and from 7 to 20 per 100,000 in Japan. MSA-P comprises approximately 70% of cases in the US and EU, whilst MSA-C comprises approximately 70% of cases in Japan.

Blood and MRI biomarkers have been evaluated in MSA patients. NfL (Neurofilament light protein) levels are increased in the cerebrospinal fluid (CSF) and plasma of patients with MSA and correlate with MSA disease severity, as measured by the unified MSA rating scale (UMSARS). An accurate estimate of NfL levels over time could help monitor MSA prognosis and help define the timepoints that could be targeted for effective treatment.

Furthermore, MSA patients with abnormal brain MRI findings have faster clinical progression of MSA, as evaluated with the UMSARS total score and UMSARS Part II (clinical examination). A recent review on the role of MRI in MSA noted that whilst MRI is a promising tool for diagnosing and monitoring disease progression; well-designed, large, prospective studies are needed before MRI biomarkers could be incorporated into a neuroimaging-supported diagnosis of MSA. The knowledge gained from this study should help improve understanding of biomarkers and other disease progression outcomes in MSA. This could allow MSA disease progression to be monitored and therefore treated more effectively. Insights into the natural course of disease in MSA patients in the EU will be combined and compared with data on the natural course of disease in MSA patients in China, as part of a larger global cohort. Specifically, the natural course of MSA will be explored in patients in China (using [Chinese versions of] the same prospective observational assessments as the current prospective protocol in the EU). This will allow for data collected prospectively during routine visits for MSA in China to be combined and compared with data collected prospectively during routine visits for MSA in the EU.

The extension part of Talisman:

The extension of Talisman will describe early MSA disease progression and mortality assessed remotely via telephone call with either the participant or care-partner in 6-month intervals up until 60 months after enrolling in extension study. The long-term extension will generate knowledge on long-term disease progression and survival in MSA.

03

Conditions studied

  • Multiple System Atrophy
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Approximately 140 patients with relatively early MSA from China and EU are expected to be enroled in this study during a 9-month enrolment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient must be aged between ≥40 and ≤75 years, at baseline.
  2. The patient must be diagnosed with possible or probable MSA of the parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C), according to the Gilman criteria (version 2).
  3. The patient must have an anticipated survival of at least 3 years in the opinion of the study investigator, at baseline.
  4. The patient had onset of motor MSA symptoms within 5 years prior to the baseline visit in the judgement of the study investigator.
  5. The patient must have an UMSARS Part I score of ≤16 (omitting question 11 on sexual function), at baseline.
  6. The patient must have normal cognition (i.e., [MoCA] score ≥22), at baseline.
  7. The patient's caregiver must have approximately 3 hours per week contact with the patient and be available and able to accompany the patient to routine clinical visits throughout the study, to provide information on the patient's functional abilities.
  8. The patient/patient's legally acceptable representative, and the patient's caregiver are willing to provide written voluntary .
  9. The patient's treatments are prescribed according to routine clinical practice and local guidelines/regulations.

Exclusion criteria

Exclusion criteria:

  1. The patient has evidence (clinical or on MRI) and/or history of any serious neurological disorder, other intracranial or systemic diseases or conditions resulting in a diagnosis other than MSA.
  2. The patient has two or more blood relatives with a history of MSA.
  3. The patient is, in the investigator's opinion, unlikely to comply with the protocol.
  4. The patient has previously been enroled in this study.
  5. The patient is a member of the study personnel or of their immediate family or is a subordinate (or immediate family member of a subordinate) to any of the study personnel.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients diagnosed with possible or probable MSA

    This protocol does not mandate the use of any treatments. No study medication will be administered as part of study participation. Any treatment that study patients receive will be prescribed according to the recommendations given in the local SmPCs.

    Diagnostic Test: plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort

Interventions

  • Diagnostic testplasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort

    Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice). These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice.

06

What researchers measure

Primary outcomes

  1. To describe early MSA disease progression changes in 6-month intervals over 12-months (i.e., baseline, 6-months, 12-months)

    Disease progression will be assessed using the Unified MSA Rating Scale (UMSARS) Part I and II (scores ranging from 0-104); higher scores indicate greater impairment

    Time frame: baseline, 6 months, 12 months

  2. Changes from baseline to approx. 6-months after baseline and approx.12- months after baseline in plasma NfL concentrations.

    Time frame: baseline, 6 months, 12 months

  3. Percentage change in brain volume in brain regions-of-interest (ROIs), as measured by volumetric MRI (vMRI).

    Time frame: baseline, 6 months, 12 months

  4. Percentage change in tissue integrity in ROIs, as measured by diffusion-tensor imaging (DTI) MRI.

    Time frame: baseline, 6 months, 12 months

Secondary outcomes

  1. To evaluate changes from baseline on the impact of disease progression on the quality of life (QoL) of the patient at 6 and 12 months

    Patient QoL will be measured by the European Quality of Life Five Dimensions questionnaire 5 level version (EQ-5D-5L)

    Time frame: baseline, 6 months, 12 months

  2. To evaluate changes from baseline on the impact of disease progression on the quality of life (QoL) of the caregiver at 6 and 12 months

    Caregiver QoL will be measured by the Parkinsonism Carers Quality of Life scale (PQoLCarers) (score range 0-104); higher score indicate worse QoL

    Time frame: baseline, 6 months, 12 months

  3. To assess changes on the burden of orthostatic hypotension at 6 and 12 months from baseline

    Othostatic hypertension will be measured by the Orthostatic Hypotension Questionnaire (OHQ) (scores ranging from 0-100); higher scores indicate greater impairment

    Time frame: baseline, 6 months, 12 months

  4. To describe occurrence of MSA subtypes and disease progression in each MSA subtype

    MSA subtype (i.e., MSA-P vs MSA-C) at each study site; disease progression will be measured by UMSARS

    Time frame: baseline, 6 months, 12 months

  5. To assess the prevalence of "responders to Levodopa" (as per clinical judgement) at baseline and who continue to respond at 6 and 12 months from baseline

    Time frame: baseline, 6 months, 12 months

  6. To describe Levodopa dose modifications from baseline to 6 and 12 months

    Time frame: baseline, 6 months, 12 months

  7. To describe patient characteristics of responders to Levodopa versus non-responders to Levodopa, including: age (in years) at MSA onset, sex (male, female), MSA diagnosis (probable versus possible), MSA subtype (MSA-P versus MSA-C).

    Time frame: baseline, 6 months, 12 months

  8. To characterise MSA symptoms and their progression over time

    MSA symptoms as per the following single items in UMSARS Part I (historical review): * Urinary incontinence (item 10) * Falling (item 8) * Speech (item 1) * Swallowing (item 2) * Walking (item 7)

    Time frame: baseline, 6 months, 12 months

  9. To assess the psychometric properties of the Chinese version of UMSARS.

    To test the reliability and validity of the Chinese version of the UMSARS

    Time frame: baseline, 6 months, 12 months

  10. To confirm the psychometric properties of the UMSARS

    To confirm the reliability and validity of the UMSARS Evaluation of UMSARS equivalence using Retrospective and Prospective Cohort data

    Time frame: baseline, 6 months, 12 months

  11. To describe early MSA disease progression and mortality assessed remotely in 6-month intervals up until 60 months after enrolling in extension study.

    Disease progression in the extension will be assessed using: * UMSARS Part I * Mortality (date and cause of death)

    Time frame: 6-month intervals up until 60 months

07

Study locations

8 sites
08

References and documents

Publications

  • Feng T, Wang H, Wang J, Tang B, Liu CF, Chen H, Mao W, Zhou Q, Rascol O, Meissner WG, Bidani A, Rieckmann A, Astrom DO, Chan P, Shang H, Cui L. Natural history and 12-month progression of multiple system atrophy in a Chinese cohort. BMC Neurol. 2026 Jun 12. doi: 10.1186/s12883-026-05037-7. Online ahead of print. PubMed 42286509 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2024, 20 months.

Of 39 observational studies under Multiple System Atrophy, half reached primary completion within 94 months of starting (the median), counting those still running; a quarter within 37. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2022
First posted
Jul 12, 2022
StartActual
Jun 25, 2022
Primary completionActual
Mar 12, 2024
CompletionEst.
May 30, 2031
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05453058
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jul 12, 2022
Start date
Jun 25, 2022
Primary completion
Mar 12, 2024
Completion
May 30, 2031 (estimated)
Last update
Dec 8, 2025

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion